This disclosure relates generally to biomarkers of cancer. More particularly, the present disclosure relates to miRNA biomarkers and their use in methods, compositions, apparatuses, devices and kits for determining an indicator that is useful for assessing a likelihood that an oral potentially malignant disorder or oral cancer is present or absent in a subject.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present invention relates to an applicator for applying functional electrical stimulation (FES) to rehabilitate a person. The applicator includes a surround for surrounding a portion of the person. One or more electrodes are locating within the surround. The electrodes may be borne by the surround, when attaching the surround to the portion, to greatly reduce set-up time.
The present disclosure relates to the field of vaccines to protect against disease caused by erythrocytic organisms, such as Plasmodium sp., and methods of making and using same.
The present disclosure relates to the field of nanobodies, therapeutic agents, compositions and methods for the prevention, amelioration and treatment of noroviral infections.
The present disclosure relates to the field of therapeutic methods for the treatment of viral infections, and more particularly latent viral infections, using modulators of intracellular calcium signalling.
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
This invention relates to a codon deoptimized severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) genome. In particular, embodiments of the invention concern a vaccine comprising live attenuated SARS-COV-2 comprising a partly codon deoptimized viral genome, SARS-COV-2 comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. The ORF1a region of the viral genome has been codon deoptimized.
The present disclosure provides immunogenic compositions and methods of inducing an immune response and/or preventing, treating or ameliorating an infection, disease or condition associated with an erythrocytic organism in a first mammal, wherein the erythrocytes are from a second mammal of a species different from the first mammal.
The present disclosure relates to compositions, kits and methods for preparing and/or analysing biological samples from a subject. These compositions, kits and methods may be useful in applications, such as diagnosing cancer and/or or determining a prognosis therefor.
The present invention relates to a method for producing a sport beverage, comprising the steps of providing malt and/or unmalted grains, providing mashing liquor produced from spent grains, processing the malt and the mashing liquor to obtain a wort, fermenting the wort by using a yeast and optionally, blending with flavour(s) and/or vitamin(s); and/or adding of sugar(s). The present invention further relates to a sport beverage obtained by said method, wherein said sport beverage is non-alcoholic or has an alcohol content of less than about 1.2 vol-%, preferably less than about 0.5 vol-%. The present invention also relates to the use of the sport beverage before and/or after physical activities.
C12C 11/11 - Post fermentation treatments, e.g. carbonation or concentration
C12C 12/00 - Processes specially adapted for making special kinds of beer
C12G 3/021 - Preparation of other alcoholic beverages by fermentation of botanical family Poaceae, e.g. wheat, millet, sorghum, barley, rye or corn
C12G 3/026 - Preparation of other alcoholic beverages by fermentation with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides, added before or during the fermentation stagePreparation of other alcoholic beverages by fermentation with flavouring ingredients added before or during the fermentation stage
C12H 1/00 - Pasteurisation, sterilisation, preservation, purification, clarification, or ageing of alcoholic beverages
TOWNSVILLE HOSPITAL AND HEALTH SERVICE (Australia)
THE STATE OF QUEENSLAND ACTING THROUGH QUEENSLAND HEALTH (Australia)
GRIFFITH UNIVERSITY (Australia)
UNIVERSITY OF QUEENSLAND (Australia)
Inventor
Chavan, Arjun
Hardwick-Greaves, Luke
Atzeni, Damon
Zhang, Patrick
Lovell, Brian
Qiu, Oliver
Liew, Alan
Dicton, Ben
Abstract
Described herein is a system (200) and method (100) of performing automated respirator fit testing. The method (100) includes the initial step (101) of receiving one or more images of a subject's face. Method (100) includes the optional step (102) of receiving biometric information about the subject. At step (103) the one or more images are processed to determine facial features of the subject's face and to output one or more facial feature vectors associated with the facial features. At step (104) the one or more facial feature vectors are input to a machine learning classification module that is trained on a database of stored face images associated with reference fit test data including one or more recommended respirator devices for each face image. At step (105), the machine learning classification module outputs one or more recommended respirator devices for the subject.
The present disclosure relates to compounds of Formula (I) and metal complexes of compounds of Formula (I), as well as pharmaceutical compositions comprising same. The present disclosure also relates to their uses in the treatment of cancer.
This disclosure relates generally to Neisseria surface moieties. More particularly, the present disclosure relates to oligosaccharides corresponding to Neisseria lipooligosaccharides and to chimeric molecules comprising these moieties for eliciting an immune response to Neisseria organisms and/or for treating or inhibiting the development of Neisseria infections.
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates generally to compositions and methods for inhibiting the replication of coronaviruses and treating diseases caused by coronavirus infection. More specifically, the invention provides nucleic acids capable of inhibiting coronavirus (e.g. SARS-CoV-2) replication and their use in treating patients infected by the virus.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
The present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to pharmaceutical compositions comprising the compound. In Formula (I), rings W, X, Y and Z may relate to various heterocyclic, heteroaryl, cycloalkyl, cycloalkenyl, and/or aryl rings. The present invention also relates to uses of the compounds in treating a disease, disorder or condition caused by viral infection. (I) R3 is selected from the group consisting of:
The present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to pharmaceutical compositions comprising the compound. In Formula (I), rings W, X, Y and Z may relate to various heterocyclic, heteroaryl, cycloalkyl, cycloalkenyl, and/or aryl rings. The present invention also relates to uses of the compounds in treating a disease, disorder or condition caused by viral infection. (I) R3 is selected from the group consisting of:
Embodiments include a computer-implemented method of pre-operative planning for patient surgery, the method including: generating a personalised pre-operative software model based on received pre-operative medical imagery and pre-operative patient movement analysis data related to movement of the patient anatomical structure of the individual patient; receiving by the least one computer processor a software definition of a surgical procedure to be performed in relation to the personalised pre-operative software model of the patient anatomical structure; generating by the least one computer processor a modified personalised post-operative software model of the patient anatomical structure; simulating by the at least one computer processor movement of the patient anatomical structure according to the modified personalised post-operative software model to generate simulation output; allowing by the least one computer processor adjustment of the personalised post-operative software model based on the simulation output; generating by the least one computer processor a personalised surgical cutting guide; and generating by the least one computer processor at least one of: 3D printing instructions based on the personalised surgical cutting guide model or personalised surgical operation instructions to transmit to a robotic surgical system for use in performing the surgical procedure.
Methods of diagnosing a subject as having post COVID-19 condition. The method may include obtaining a biological sample from the subject; carrying out an assay on the biological sample for detecting altered functionality of at least one transient receptor potential (TRP) ion channel; and identifying the subject as having post COVID-19 condition when the property that is diagnostic of post COVID-19 condition is detected using the assay.
NN-oxide, pharmaceutically acceptable salt, prodrug or stereoisomer thereof. The present disclosure also relates to pharmaceutical compositions comprising the compound. The present disclosure further relates to methods and uses of the compound in treating or preventing a disease, disorder or condition caused by viral infection in a subject.
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present disclosure relates to methods, uses and pharmaceutical compositions for the treatment and/or prophylaxis of bacterial infections caused by a bacteria selected from the group consisting of Neisseria gonorrhoeae, Neisseria meningitidis, nontypeable Haemophilus influenzae, Campylobacter and Helicobacter pylori, comprising administering an effective amount of PBT2.
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Australia)
GRIFFITH UNIVERSITY (Australia)
Inventor
Adams, Tina Sherrie
Hart, Christopher John Saville
Ryan, John Henry
Riches, Andrew Geoffrey
Abstract
The present disclosure relates to compounds that find application as therapeutics. In particular, the disclosure relates to compounds of Formula (I) or Formula (II) and their pharmaceutically acceptable salt, solvates, or stereoisomers thereof, to pharmaceutical compositions containing such compounds, to methods for using such compounds in the prevention and/or treatment of Giardiasis, and to related uses.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE (Switzerland)
UNIVERSITÄT BASEL (Switzerland)
Inventor
Jennings, Michael P.
Day, Christopher J.
Pluschke, Gerd
Abstract
This disclosure relates generally to the use of compounds that inhibit binding of Plasmodium cysteine-rich protective antigen (CyRPA) to glycans of cells that are susceptible to infection by Plasmodium pathogens, including glycans terminating with α2-6-linked sialic acid, in methods, compositions and kits for inhibiting the interaction of a Plasmodium pathogen to Plasmodium-binding glycan-expressing cells, including α2-6-linked sialic acid-expressing cells such as erythrocytes, and for treating or inhibiting the development of malaria.
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
The present disclosure relates generally to biomarkers of fibrosis. More particularly, the present disclosure relates to salivary biomarkers and their use in methods, apparatuses, compositions and kits for determining an indicator that is useful for assessing a likelihood of a presence, absence or degree of liver fibrosis in a human subject. In particular embodiments, the disclosed methods, apparatuses, compositions and kits are used to determine an indicator for assessing a likelihood of a presence, absence or development of liver cirrhosis in a subject.
A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
In one aspect the invention relates to the use of single nucleotide polymorphisms (SNPs) in transient receptor potential (TRP) ion channel, acetylcholine receptor (AchR) and/or adrenergic receptor (ADR) genes as probes, tools or reagents for identifying, screening, diagnosing, monitoring or managing/treating subjects with, or predisposed to, medical conditions (or symptoms thereof), such as chronic fatigue syndrome (CFS), myalgic encephalomyelitis (ME), Gulf war syndrome (GWS), irritable bowel syndrome (IBS), multiple chemical sensitivity (MCS), fibromyalgia, and migraine, as well as some medical conditions caused by dysregulation in calcium, acetylcholine, TRP and ADR, and dysregulation in the gastrointestinal, cardiovascular, neurological, genitourinary and immune systems. In another aspect the invention relates to methods, kits and assays for identifying, screening, diagnosing, monitoring or managing/treating subjects with one or more of those medical conditions or symptoms.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
24.
IMMUNOSTIMULATORY COMPOSITIONS COMPRISING SOLUBLE PARASITE EXTRACTS AND USES THEREOF
Disclosed are compositions for stimulating a protective or therapeutic immune response to an apicomplexan parasite such as those from the Plasmodium or Babesia genus. More particularly, the compositions comprise a soluble parasite extract. The extract may be free of red blood cell components and/or contained in or associated with a particle such as a liposome. The compositions and methods disclosed herein are particularly useful in the prevention and treatment of parasitic diseases.
The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRO). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS·Na), in the therapy of a range of extracellular histone mediated ailments in subjects.
The present disclosure relates generally to biomarkers of cancer. More particularly, the present disclosure relates to extracellular vesicle biomarkers and their use in methods, apparatuses, compositions and kits for determining an indicator that is useful for assessing a likelihood of a decreased or poor survival prognosis or an increased or good survival prognosis in a glioblastoma patient. The disclosed methods, apparatuses, compositions and kits are useful for monitoring prognosis of a glioblastoma patient before and after exposure to a treatment regimen, and for managing treatment of a glioblastoma patient.
Disclosed herein are biomarkers of cancer. More particularly, the present disclosure relates to miRNA biomarkers and their use in methods, compositions, apparatuses, devices and kits for determining an indicator that is useful for assessing a likelihood that oropharyngeal cancer is present or absent in a human subject, or for assessing a likelihood of a human subject with OPC having a poor survival prognosis or good survival prognosis.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
This invention relates, inter alia, to an immunogenic fragment of a Neisserial Heparin Binding Antigen (NHBA) protein of Neisseria gonorrhoeae (SEQ ID NO: 1) for the prevention and treatment of Neisseria gonorrhoeae or gonococcal- or meningococcal-associated diseases and conditions. In some embodiments, the immunogenic fragment corresponds to a C-terminal fragment of the protein (SEQ ID NO: 2).
A high-frequency rotary transformer, a machine and a high frequency transformer are defined that are simpler to manufacture and less expensive than existing transformers and machines. The high-frequency rotary transformer includes: a primary transformer core comprising a plurality of primary core elements, each defining a primary transformer winding portion; a secondary transformer core comprising a plurality of secondary core elements, each defining a secondary transformer winding portion; a primary winding associated with each of the primary core elements; and a secondary winding associated with each of the secondary core elements. The primary transformer core and the secondary transformer core together define a transformer core having a flux pathway linking the primary and secondary windings, and the primary transformer core and the secondary transformer core are configured to rotate relative to each other. A magnetic flux concentrator may be used to direct magnetic flux towards an inside of the rotary transformer.
A method of calculating in vivo force on an anterior cruciate ligament (ACL) by measuring one or more biomechanical properties during a biomechanical screening task to obtain one or more biomechanical datum from the measured one or more biomechanical properties, and calculating a total load on an anterior cruciate ligament from an ACL force model using the one or more biomechanical datum as inputs to the ACL force model. The ACL force model is defined by FACL=FACLsag+FACLfront+FACLtrans+ΣjCTj, wherein FACL is the total force on the ACL, FACLsag is the force on the ACL in a sagittal plane, FACLfront is the force on the ACL in the frontal plane, FACLtrans is the force on the ACL in the transverse plane, and CTj is the ACL force interaction relationships among the sagittal-frontal (SF), sagittal-transverse (ST), and frontal-transverse (FT) planes, where j=SF, ST, FT.
A61B 5/313 - Input circuits therefor specially adapted for particular uses for electromyography [EMG]
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
The present invention relates to an applicator for applying functional electrical stimulation (FES) to rehabilitate a person. The applicator includes a surround for surrounding a portion of the person. One or more electrodes are locating within the surround. The electrodes may be borne by the surround, when attaching the surround to the portion, to greatly reduce set-up time.
A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/256 - Wearable electrodes, e.g. having straps or bands
A61B 5/259 - Means for maintaining electrode contact with the body using adhesive means, e.g. adhesive pads or tapes using conductive adhesive means, e.g. gels
Methods of eliciting and/or modulating immune responses, therapeutic methods, and antigen delivery methods that include the step of administering a protein particle derived from a cell, the protein particle comprising a diphtheria toxin Cross Reacting Material (CRM) amino acid sequence are disclosed. Included are diagnostic methods using the protein particle derived from a cell, the protein particle comprising a diphtheria toxin CRM amino acid sequence. The methods disclosed herein may be useful as an antigen carrier delivery system.
A mutant subtilase cytotoxin B subunit protein is provided which can bind glycans having α2-3-linked N-glycolylneuraminic acid and glycans having α2-6-linked N-glycolylneuraminic acid. The mutant SubB protein has deletions of one or more of the amino acid sequence TTSTE and has a previously undescribed ability to bind glycans having α2-6-linked N-glycolylneuraminic acid, while not losing the ability to bind glycans having α2-3-linked N-glycolylneuraminic acid.
A61K 39/018 - Babesia antigens, e.g. Theileria antigens
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
The present disclosure relates to compositions, kits and methods for preparing and/or analysing biological samples from a subject. These compositions, kits and methods may be useful in applications, such as diagnosing cancer and/or or determining a prognosis therefor.
This disclosure relates generally to Neisseria surface moieties. More particularly, the present disclosure relates to oligosaccharides corresponding to Neisseria lipooligosaccharides and to chimeric molecules comprising these moieties for eliciting an immune response to Neisseria organisms and/or for treating or inhibiting the development of Neisseria infections.
C07K 14/34 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Corynebacterium (G)
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
A sensing platform comprises a semiconductor junction, in particular a SiC/Si heterojunction, with a pair of electrodes located on a surface of an upper layer of the semiconductor junction in a spaced apart relationship. The sensing platform comprises a light source above the surface of the upper layer to illuminate a part of the surface of the semiconductor junction comprising at least part of one of the electrodes to create a lateral potential gradient between the pair of electrodes through the photovoltaic effect in the semiconductor. Parameters, such as force and temperature, are detected based on measuring a change in electrical resistance of the semiconductor material due to the piezoresistive effect and/or the thermoresistive effect. An external potential difference can be applied between the pair of electrodes to create a tuning current to modulate the piezoresistive and thermoresistive effects in the semiconductor junction. The sensing platform is used for highly sensitive force sensors and highly sensitive temperature sensors.
G01L 9/00 - Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by electric or magnetic pressure-sensitive elementsTransmitting or indicating the displacement of mechanical pressure-sensitive elements, used to measure the steady or quasi-steady pressure of a fluid or fluent solid material, by electric or magnetic means
G01L 19/00 - Details of, or accessories for, apparatus for measuring steady or quasi-steady pressure of a fluent medium insofar as such details or accessories are not special to particular types of pressure gauges
H01L 31/08 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof in which radiation controls flow of current through the device, e.g. photoresistors
A securement device for securement of a catheter connecting assembly to a body of a patient wherein the catheter connecting assembly includes two or more ports adapted to be coupled with the catheter, each port being formed by a respective port body wherein the ports are adapted to be fluidly coupled to a catheter hub of a catheter, the securement device comprising: a base having a continuous top surface and a continuous bottom surface wherein at least a portion of the top surface comprises an antimicrobial layer and wherein at least a portion of the bottom surface comprises an adhesive for attachment of the base to the body of the patient and wherein the base is dimensioned to prevent direct contact between said ports and body of the patient; and one or more retention formations located on the top surface of the base for receiving and retaining at least a portion of a housing comprising said one or more port bodies adapted to be coupled with a terminal end of the catheter.
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I) In which R3 is selected from the group consisting of optionally substituted N-linked naphthotriazole, optionally substituted N-linked indazole, and certain N-linked triazoles. The present invention also relates to uses of the compounds in treating a disease, disorder or condition caused by viral infection, and pharmaceutical compositions comprising the compounds.
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I) In which R3 is selected from the group consisting of optionally substituted N-linked naphthotriazole, optionally substituted N-linked indazole, and certain N-linked triazoles. The present invention also relates to uses of the compounds in treating a disease, disorder or condition caused by viral infection, and pharmaceutical compositions comprising the compounds.
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
The present invention relates to a rehabilitation system for rehabilitating a person with a neurological condition, such as a spinal cord injury (SCI). The system includes exercise equipment for enabling the person to exercise. One or more sensors are provided for sensing information from the person during exercise. The system also includes a model of the exercising person configured to receive the sensed information from the sensors and generate electrical stimulation for the person. Advantageously, the personalized computer model may be used to generate suitable electrical stimulation for the person, and avoid excessive stresses on the person which can lead to the fracturing of bones.
A63B 24/00 - Electric or electronic controls for exercising apparatus of groups
A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
A63B 71/06 - Indicating or scoring devices for games or players
A63B 22/06 - Exercising apparatus specially adapted for conditioning the cardio-vascular system, for training agility or co-ordination of movements with rotating cycling movement
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
The present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to pharmaceutical compositions comprising the compound. In Formula (I), rings W, X, Y and Z may relate to various heterocyclic, heteroaryl, cycloalkyl, cycloalkenyl, and/or aryl rings. The present invention also relates to uses of the compounds in treating a disease, disorder or condition caused by viral infection. (I) R3 is selected from the group consisting of:
GOLD COAST HOSPITAL AND HEALTH SERVICE (Australia)
Inventor
Good, Michael
Pandey, Manisha
Gerrard, John Gregory
Abstract
The present disclosure provides immunogenic compositions and methods of inducing an immune response and/or preventing, treating or ameliorating an infection, disease or condition associated with SARS-CoV-2 in a subject with such immunogenic compositions.
The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of NET mediated ailments in subjects.
Apparatus for medical rehabilitation; instruments for
patient rehabilitation; electrodes for medical purposes;
sensors (measurement apparatus) for medical use.
This invention relates to a vaccine comprising live attenuated Zika virus comprising a partly codon deoptimized viral genome, a Zika virus comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. is deoptimized along the nonstructural ZIKV coding region. In some embodiments, the non-structural region of the viral genome is codon deoptimized, and preferably one or more of the genes NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are codon deoptimized.
This invention relates generally to polynucleotides, polypeptides, compositions, methods and uses for eliciting an immune response to Neisseria, methods for immunizing a subject against a Neisseria infection, and methods for preventing and/or treating a Neisseria infection in a subject. More particularly, the invention relates to antigenic Neisseria polypeptides and encoding polynucleotides, and related uses and methods, including use for preparing compositions and medicaments for eliciting an immune response to Neisseria, for immunizing a subject against a Neisseria infection, and for preventing and/or treating a Neisseria infection in a subject. The invention also relates to methods for producing therapeutic anti-Neisseria antigen-binding molecules, and therapeutic uses of those antigen-binding molecules.
This invention relates to a codon deoptimized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome. In particular, embodiments of the invention concern a vaccine comprising live attenuated SARS-CoV-2 comprising a partly codon deoptimized viral genome, SARS-CoV-2 comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. The ORF1a region of the viral genome has been codon deoptimized.
A system for providing ventricular assistance to a heart of a subject, the system including a balloon configured to be inserted into a ventricle of the heart, wherein the balloon is configured to differentially inflate to thereby urge blood towards a semilunar valve of the ventricle; a fluid conduit in fluid communication with the balloon; a pumping mechanism attached to the fluid conduit; and, a controller configured to control the pumping mechanism to thereby selectively supply fluid into the balloon so as to inflate the balloon at least partially in accordance with the cardiac cycle.
A61M 60/17 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart inside a ventricle, e.g. intraventricular balloon pumps
A61M 60/295 - Balloon pumps for circulatory assistance
A61M 60/497 - Details relating to driving for balloon pumps for circulatory assistance
A61M 60/515 - Regulation using real-time patient data
A high-frequency rotary transformer, a machine and a high frequency transformer are defined that are simpler to manufacture and less expensive than existing transformers and machines. The high-frequency rotary transformer includes: a primary transformer core comprising a plurality of primary core elements, each defining a primary transformer winding portion; a secondary transformer core comprising a plurality of secondary core elements, each defining a secondary transformer winding portion; a primary winding associated with each of the primary core elements; and a secondary winding associated with each of the secondary core elements. The primary transformer core and the secondary transformer core together define a transformer core having a flux pathway linking the primary and secondary windings, and the primary transformer core and the secondary transformer core are configured to rotate relative to each other. A magnetic flux concentrator may be used to direct magnetic flux towards an inside of the rotary transformer.
H01F 19/04 - Transformers or mutual inductances suitable for handling frequencies considerably beyond the audio range
H01F 21/06 - Variable inductances or transformers of the signal type continuously variable, e.g. variometers by movement of core or part of core relative to the windings as a whole
H01F 30/12 - Two-phase, three-phase or polyphase transformers
The present disclosure relates to peptides comprising an amino acid sequence set forth in SEQ ID NO: 1 or 2. Methods of using these peptides to treat or prevent an infection caused by an angiotensin-converting enzyme 2 (ACE2)-interacting coronavirus, elicit an immune response to an ACE2-interacting coronavirus, detect an infection by an ACE2-interacting coronavirus, or identify agents which inhibit the interaction of an ACE2-interacting coronavirus with the ACE2 receptor, are further disclosed. Furthermore, this disclosure pertains to methods of treating a coronavirus infection comprising the administration of an ACE2- interacting compound, and novel compounds for this purpose.
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/655 - Azo (—N=N—), diazo (=N2), azoxy (N—O—N or N(=O)—N), azido (—N3) or diazoamino (—N=N—N) compounds
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
A high-frequency rotary transformer, a machine and a high frequency transformer are defined that are simpler to manufacture and less expensive than existing transformers and machines. The high-frequency rotary transformer includes: a primary transformer core comprising a plurality of primary core elements, each defining a primary transformer winding portion; a secondary transformer core comprising a plurality of secondary core elements, each defining a secondary transformer winding portion; a primary winding associated with each of the primary core elements; and a secondary winding associated with each of the secondary core elements. The primary transformer core and the secondary transformer core together define a transformer core having a flux pathway linking the primary and secondary windings, and the primary transformer core and the secondary transformer core are configured to rotate relative to each other. A magnetic flux concentrator may be used to direct magnetic flux towards an inside of the rotary transformer.
H01F 19/04 - Transformers or mutual inductances suitable for handling frequencies considerably beyond the audio range
H01F 21/06 - Variable inductances or transformers of the signal type continuously variable, e.g. variometers by movement of core or part of core relative to the windings as a whole
Research Institute at Nationwide Children's Hospital (USA)
Inventor
Jennings, Michael P.
Edwards, Jennifer L.
Day, Christopher J.
Mak, Johnson
Abstract
The present disclosure relates to the use of ligands of complement receptor 3, including ligands of the I domain of the alpha subunit of this receptor, in methods, compositions and articles/devices for inhibiting the interaction of pathogens to a complement receptor 3-expressing cell and for treating or inhibiting the development of infections caused by such pathogens.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
Provided herein are methods of immunizing against, treating or preventing streptococcal toxic shock syndrome in a subject, by administration of a group A Streptococcus M protein, inclusive of fragments, variants or derivatives thereof, or an antibody that binds, or is raised against the M protein and optionally a group A Streptococcus superantigen protein, inclusive of fragments, variants or derivatives thereof, or an antibody or antibody fragment that binds, or is raised against, the superantigen protein.
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
A quantitative sensor is provided for the in situ detection of chlorine, the sensor comprises a substantially planar hydrophobic gas permeable membrane having a sampling side and an opposing analytical side. The analytical side of the membrane is disposed within a colorimetric chamber comprising a chromogenic agent. Also provided is an optical detector in the colorimetric chamber to measure a colour of the chromogenic agent. In use chlorine in the sample permeates through the pores of the gas permeable membrane causing the chromogenic agent to change colour in an amount directly proportional to the amount of chlorine in the sample. The colour change is detectable by the optical detector.
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
G02F 1/15 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect
B01D 61/00 - Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltrationApparatus, accessories or auxiliary operations specially adapted therefor
G01N 21/75 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
56.
Compounds for treating and preventing extracellular histone mediated pathologies
The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of extracellular histone mediated ailments in subjects.
This invention relates, inter alia, to an immunogenic fragment of a Neisserial Heparin Binding Antigen (NHBA) protein of Neisseria gonorrhoeae (SEQ ID NO: 1) for the prevention and treatment of Neisseria gonorrhoeae or gonococcal- or meningococcal-associated diseases and conditions. In some embodiments, the immunogenic fragment corresponds to a C-terminal fragment of the protein (SEQ ID NO: 2).
C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Neisseria gonorrhoeaeNeisseria gonorrhoeaeNeisseria gonorrhoeae or gonococcal- or meningococcal-associated diseases and conditions. In some embodiments, the immunogenic fragment corresponds to a C-terminal fragment of the protein (SEQ ID NO: 2).
C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
A61K 39/00 - Medicinal preparations containing antigens or antibodies
PlasmodiumBabesiaBabesia genus. More particularly, the compositions comprise a soluble parasite extract. The extract may be free of red blood cell components and/or contained in or associated with a particle such as a liposome. The compositions and methods disclosed herein are particularly useful in the prevention and treatment of parasitic diseases.
A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
A61K 39/018 - Babesia antigens, e.g. Theileria antigens
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
An electrohydrodynamic atomization device comprising a nozzle for emitting a stream of atomized liquid, the nozzle being connected to a liquid source; a nozzle electrode associated with the nozzle; a reference electrode; wherein the nozzle and reference electrodes co-operate to generate an electric field therebetween; a source of alternating electric current connected to the nozzle electrode and the reference electrode; and wherein the nozzle, nozzle electrode, reference electrode, and source of alternating current, are arranged so that a liquid emitted by the nozzle is atomised into positively and negatively charged particles, the positively and negatively charged particles combining downstream of the nozzle to form neutral liquid particles. The reference electrode may be situated upstream of an outlet of the nozzle. A corresponding method is also provided.
B05B 5/00 - Electrostatic spraying apparatusSpraying apparatus with means for charging the spray electricallyApparatus for spraying liquids or other fluent materials by other electric means
63.
PROTEIN PARTICLES COMPRISING A DIPHTHERIA TOXIN CROSS REACTING MATERIAL (CRM) AMINO ACID SEQUENCE AND USES THEREOF
Methods of eliciting and/or modulating immune responses, therapeutic methods, and antigen delivery methods that include the step of administering a protein particle derived from a cell, the protein particle comprising a diphtheria toxin Cross Reacting Material (CRM) amino acid sequence are disclosed. Included are diagnostic methods using the protein particle derived from a cell, the protein particle comprising a diphtheria toxin CRM amino acid sequence. The methods disclosed herein may be useful as an antigen carrier delivery system.
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I) In which R3 is selected from the group consisting of optionally substituted N-linked naphthotriazole, optionally substituted N-linked indazole, and certain N-linked triazoles. The present invention also relates to uses of the compounds in treating a disease, disorder or condition caused by viral infection, and pharmaceutical compositions comprising the compounds.
C07D 405/02 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
33 is selected from the group consisting of optionally substituted N-linked naphthotriazole, optionally substituted N-linked indazole, and certain N-linked triazoles. The present invention also relates to uses of the compounds in treating a disease, disorder or condition caused by viral infection, and pharmaceutical compositions comprising the compounds.
C07D 405/02 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A Streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 5 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A sensing platform comprises a semiconductor junction, in particular a SiC/Si heterojunction, with a pair of electrodes located on a surface of an upper layer of the semiconductor junction in a spaced apart relationship. The sensing platform comprises a light source above the surface of the upper layer to illuminate a part of the surface of the semiconductor junction comprising at least part of one of the electrodes to create a lateral potential gradient between the pair of electrodes through the photovoltaic effect in the semiconductor. Parameters, such as force and temperature, are detected based on measuring a change in electrical resistance of the semiconductor material due to the piezoresistive effect and/or the thermoresistive effect. An external potential difference can be applied between the pair of electrodes to create a tuning current to modulate the piezoresistive and thermoresistive effects in the semiconductor junction. The sensing platform is used for highly sensitive force sensors and highly sensitive temperature sensors.
G01K 7/16 - Measuring temperature based on the use of electric or magnetic elements directly sensitive to heat using resistive elements
H10N 15/10 - Thermoelectric devices using thermal change of the dielectric constant, e.g. working above and below the Curie point
H10N 30/85 - Piezoelectric or electrostrictive active materials
G01L 1/18 - Measuring force or stress, in general using properties of piezo-resistive materials, i.e. materials of which the ohmic resistance varies according to changes in magnitude or direction of force applied to the material
G01L 9/00 - Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by electric or magnetic pressure-sensitive elementsTransmitting or indicating the displacement of mechanical pressure-sensitive elements, used to measure the steady or quasi-steady pressure of a fluid or fluent solid material, by electric or magnetic means
H01L 23/00 - Details of semiconductor or other solid state devices
H01L 29/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details of semiconductor bodies or of electrodes thereof
H01L 31/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
A sensing platform comprises a semiconductor junction, in particular a SiC/Si heterojunction, with a pair of electrodes located on a surface of an upper layer of the semiconductor junction in a spaced apart relationship. The sensing platform comprises a light source above the surface of the upper layer to illuminate a part of the surface of the semiconductor junction comprising at least part of one of the electrodes to create a lateral potential gradient between the pair of electrodes through the photovoltaic effect in the semiconductor. Parameters, such as force and temperature, are detected based on measuring a change in electrical resistance of the semiconductor material due to the piezoresistive effect and/or the thermoresistive effect. An external potential difference can be applied between the pair of electrodes to create a tuning current to modulate the piezoresistive and thermoresistive effects in the semiconductor junction. The sensing platform is used for highly sensitive force sensors and highly sensitive temperature sensors.
G01K 7/16 - Measuring temperature based on the use of electric or magnetic elements directly sensitive to heat using resistive elements
G01L 1/18 - Measuring force or stress, in general using properties of piezo-resistive materials, i.e. materials of which the ohmic resistance varies according to changes in magnitude or direction of force applied to the material
G01L 9/00 - Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by electric or magnetic pressure-sensitive elementsTransmitting or indicating the displacement of mechanical pressure-sensitive elements, used to measure the steady or quasi-steady pressure of a fluid or fluent solid material, by electric or magnetic means
H01L 23/00 - Details of semiconductor or other solid state devices
H01L 29/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details of semiconductor bodies or of electrodes thereof
H01L 31/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
H01L 35/00 - SEMICONDUCTOR DEVICES; ELECTRIC SOLID STATE DEVICES NOT OTHERWISE PROVIDED FOR - Details thereof
H01L 41/00 - SEMICONDUCTOR DEVICES; ELECTRIC SOLID STATE DEVICES NOT OTHERWISE PROVIDED FOR - Details thereof
69.
BIOSPINE: A DIGTIAL TWIN NEUROREHABILITATION SYSTEM
The present invention relates to a rehabilitation system for rehabilitating a person with a neurological condition, such as a spinal cord injury (SCI). The system includes exercise equipment for enabling the person to exercise. One or more sensors are provided for sensing information from the person during exercise. The system also includes a model of the exercising person configured to receive the sensed information from the sensors and generate electrical stimulation for the person. Advantageously, the personalized computer model may be used to generate suitable electrical stimulation for the person, and avoid excessive stresses on the person which can lead to the fracturing of bones.
A securement device for securement of a catheter connecting assembly to a body of a patient wherein the catheter connecting assembly includes two or more ports adapted to be coupled with the catheter, each port being formed by a respective port body wherein the ports are adapted to be fluidly coupled to a catheter hub of a catheter, the securement device comprising: a base having a continuous top surface and a continuous bottom surface wherein at least a portion of the top surface comprises an antimicrobial layer and wherein at least a portion of the bottom surface comprises an adhesive for attachment of the base to the body of the patient and wherein the base is dimensioned to prevent direct contact between said ports and body of the patient; and one or more retention formations located on the top surface of the base for receiving and retaining at least a portion of a housing comprising said one or more port bodies adapted to be coupled with a terminal end of the catheter.
An optical beam scanner, including: a body composed of an electro-optically active material and having formed therein a plurality of optical waveguides arranged to define a branching tree of optical paths, the optical waveguides including at least one input waveguide and a plurality of mutually spaced output waveguides; and electrodes located at each of a plurality of junctions of the branching tree and configured to control optical coupling between adjacent portions of corresponding ones of the optical waveguides such that optical signals received at the input waveguide can be selectively and dynamically directed to any selected one of the mutually spaced output waveguides by applying corresponding electrical signals to corresponding ones of the electrodes to control the optical coupling at each junction of an optical path of the branching tree therebetween.
The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of ß-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of NET mediated ailments in subjects.
This invention relates to the use of zinc(II) salts in combination with a zinc ionophore to resensitize a previously resistant pathogenic bacteria to an antibiotic. Methods of restoring the sensitivity of a resistant pathogenic bacterium to an antibiotic comprising administering a zinc ionophore in combination with a zinc(II) salt and methods of treating a bacterial infection comprising administering a zinc ionophore in combination with a zinc (II) salt concurrently and/or sequentially with administration of a therapeutically effective amount of an antibiotic is also described.
The present invention relates to a three-dimensional multiphasic synthetic tissue scaffold comprising first, second and third compartments, wherein: each said compartment comprises distinct microstructural, and/or chemical, and/or mechanical properties, and is connected with at least one other compartment of the scaffold via a continuous interface; the tissue scaffold is porous; and the external morphology of the tissue scaffold mimics that of a mammalian joint or a component thereof. The invention further relates to a method for producing the three dimensional multiphasic synthetic tissue scaffold using a polymeric material, the method comprising using a three-dimensional (3D) bioprinter to print the tissue scaffold by continuously deposit the polymeric material onto a platform until the tissue scaffold is produced in its entirety.
The present invention relates to a binding polypeptide specifically binding to an epitope comprised in an amino acid sequence corresponding to amino acids 250 to 300 of the norovirus genotype II.10 capsid polypeptide, and to a polynucleotide encoding the same. The present invention further relates to a composition comprising the binding polypeptide according to the present invention and a carrier, and to the binding polypeptide or the composition comprising the same use in diagnosis and/or for use in medicine. Further more, the present invention relates to kits, devices, vaccines, methods, and uses related to the binding polypeptide of the present invention.
This invention relates generally to polynucleotides, polypeptides, compositions, methods and uses for eliciting an immune response to Neisseria, methods for immunizing a subject against a Neisseria infection, and methods for preventing and/or treating a Neisseria infection in a subject. More particularly, the invention relates to antigenic Neisseria polypeptides and encoding polynucleotides, and related uses and methods, including use for preparing compositions and medicaments for eliciting an immune response to Neisseria, for immunizing a subject against a Neisseria infection, and for preventing and/or treating a Neisseria infection in a subject. The invention also relates to methods for producing therapeutic anti-Neisseria antigen-binding molecules, and therapeutic uses of those antigen-binding molecules.
NeisseriaNeisseriaNeisseriaNeisseriaNeisseriaNeisseriaNeisseriaNeisseriaNeisseria antigen-binding molecules, and therapeutic uses of those antigen-binding molecules.
A system for providing ventricular assistance to a heart of a subject, the system including a balloon configured to be inserted into a ventricle of the heart, wherein the balloon is configured to differentially inflate to thereby urge blood towards a semilunar valve of the ventricle; a fluid conduit in fluid communication with the balloon; a pumping mechanism attached to the fluid conduit; and, a controller configured to control the pumping mechanism to thereby selectively supply fluid into the balloon so as to inflate the balloon at least partially in accordance with the cardiac cycle.
A sensor for the in situ detection of a target chemical species, comprising a gas permeable membrane having a sampling side and an opposing analytical side, wherein the sampling side of the membrane is capable of receiving a sample and the membrane is permeable to target chemical species present in the sample. A weak acid or a weak base is in contact with the analytical side of the membrane, and a conductivity detector is in contact with the weak acid or weak base. In use, target chemical species present in the sample permeate through the membrane and react with the weak acid or weak base, producing ionic species and changing the conductivity.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G01N 27/12 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluidInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon reaction with a fluid
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
This invention relates to a vaccine comprising live attenuated Zika virus comprising a partly codon deoptimized viral genome, a Zika virus comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. is deoptimized along the nonstructural ZIKV coding region. In some embodiments, the non-structural region of the viral genome is codon deoptimized, and preferably one or more of the genes NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are codon deoptimized.
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (USA)
Inventor
Jennings, Michael P.
Edwards, Jennifer L.
Day, Christopher J.
Mak, Johnson
Abstract
The present disclosure relates to the use of ligands of complement receptor 3, including ligands of the I domain of the alpha subunit of this receptor, in methods, compositions and articles/devices for inhibiting the interaction of pathogens to a complement receptor 3-expressing cell and for treating or inhibiting the development of infections caused by such pathogens.
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (USA)
Inventor
Jennings, Michael P.
Edwards, Jennifer L.
Day, Christopher J.
Mak, Johnson
Abstract
The present disclosure relates to the use of ligands of complement receptor 3, including ligands of the l domain of the alpha subunit of this receptor, in methods, compositions and articles/devices for inhibiting the interaction of pathogens to a complement receptor 3-expressing cell and for treating or inhibiting the development of infections caused by such pathogens.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (USA)
Inventor
Jennings, Michael P.
Edwards, Jennifer L.
Day, Christopher J.
Mak, Johnson
Abstract
The present disclosure relates to the use of ligands of complement receptor (3), including ligands of the I domain of the alpha subunit of this receptor, in methods, compositions and articles/devices for inhibiting the interaction of pathogens to a complement receptor 3-expressing cell and for treating or inhibiting the development of infections caused 5 by such pathogens.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A silicon carbide (SiC) Schottky diode comprises a layer of N-type SiC and a layer of P-type SiC in contact with the layer of N-type SiC creating a P-N junction. An anode is in contact with both the layer of N-type SiC and the layer of P-type SiC creating Schottky contacts between the anode and both the layer of N-type SiC and the layer of P-type SiC. An edge of the layer of P-type SiC is electrically active and comprises a tapered negative charge density at the P-N junction, which can be achieved by a tapered or sloping edge the layer of P-type SiC.
H01L 29/16 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only elements of Group IV of the Periodic System in uncombined form
H01L 29/06 - Semiconductor bodies characterised by the shapes, relative sizes, or dispositions of the semiconductor regions
A mutant subtilase cytotoxin B subunit protein is provided which can bind glycans having α2-3-linked N-glycolylneuraminic acid and glycans having α2-6-linked N-glycolylneuraminic acid. The mutant SubB protein has deletions of one or more of the amino acid sequence TTSTE and has a previously undescribed ability to bind glycans having α2-6-linked N-glycolylneuraminic acid, while not losing the ability to bind glycans having α2-3-linked N-glycolylneuraminic acid.
Provided herein are methods of immunizing against, treating or preventing streptococcal toxic shock syndrome in a subject, by administration of a group A streptococcus M protein, inclusive of fragments, variants or derivatives thereof, or an antibody that binds, or is raised against the M protein and optionally a group A streptococcus superantigen protein, inclusive of fragments, variants or derivatives thereof, or an antibody or antibody fragment that binds, or is raised against, the superantigen protein.
A61K 39/40 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum bacterial
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
Provided herein are methods of immunizing against, treating or preventing streptococcal toxic shock syndrome in a subject, by administration of a group A streptococcus M protein, inclusive of fragments, variants or derivatives thereof, or an antibody that binds, or is raised against the M protein and optionally a group A streptococcus superantigen protein, inclusive of fragments, variants or derivatives thereof, or an antibody or antibody fragment that binds, or is raised against, the superantigen protein.
A61K 39/40 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum bacterial
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
The invention relates to methods of eliciting an immune response to group A streptococcal bacteria in a mammal, the method including the step of administering to the mammal an effective amount of a composition comprising an isolated p145 peptide of SEQ ID NO: 56 and/or a p145 peptide variant having an amino acid sequence at least 90% identical to SEQ ID NO: 56, and an isolated SpyCEP peptide of SEQ ID NO: 18 and/or a SpyCEP peptide variant having an amino acid sequence at least 90% identical to SEQ ID NO: 18.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
90.
Vaccine comprising drug and parasite administration
Apicomplexan parasites or red blood cells infected with apicomplexan parasites are administered to an animal in combination with a delayed death agent that initially allows parasite replication but subsequently kills the apicomplexan parasites. This allows the elicitation of an immune response by the animal while preventing the parasites producing a serious infection of the animal. The apicomplexan parasites may be malaria or babesia parasites. The delayed death agent may be a tetracycline class antibiotic, a macrolide antibiotic or a lincosamide antibiotic.
A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
A01K 67/027 - New or modified breeds of vertebrates
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A method of N- or O-sulfation of a compound is described whereby the use of a co-solvent system comprising a participating component and a non-participating component, during the sulfation reaction, allows for the non-participating component to actively sequester the participating component away from the sulfated reaction product. This has benefits in decreasing the likelihood or extent of desulfation of the sulfated product and may result in precipitation of the sulfated product thereby allowing for simple collection.
The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ß-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of extracellular histone mediated ailments in subjects.
The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of extracellular histone mediated ailments in subjects.
The invention relates to a vaccine comprising live attenuated recombinant alphavirus comprising mutated capsid protein. The invention also relates to a method of preventing a subject from contracting an alphaviral infection that would otherwise produce clinical signs of disease. In an embodiment the mutated capsid protein is Chikungunya virus (CHIKV) capsid protein having a mutated nucleolar localisation signal/sequence (NoLS), preferably the mutant NLS 101/95.
Disclosed herein are coatings for at least one surface of an object, or a portion of said surface, which may support the formation of naked liquid marbles. The coating may be hydrophobic or superhydrophobic, and may comprise: an aliphatic hydrocarbon or petroleum ether; a solvent; nanoparticles, a siloxane, or a mixture thereof; and a polymer which may act as binder. Also disclosed herein are methods of coating a surface, or at least a portion thereof, and the use of said coated surfaces in the formation and applications of naked liquid marbles.
C09D 123/00 - Coating compositions based on homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bondCoating compositions based on derivatives of such polymers
C09D 7/00 - Features of coating compositions, not provided for in group Processes for incorporating ingredients in coating compositions
C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
C09D 1/00 - Coating compositions, e.g. paints, varnishes or lacquers, based on inorganic substances
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
96.
APPARATUS FOR AND METHODS OF REMOVING FLUID FROM A CELL CULTURE
An apparatus for removing fluid from a cell culture comprising the fluid and one or more multicellular spheroids, the apparatus comprising: a body having an conduit terminating at an opening; and a filter extending across the opening, the filter having a pore size of less than the diameter of the one or more multicellular spheroids so as to prevent the one or more multicellular spheroids from passing through the filter and into the conduit whilst allowing the fluid to pass through the filter and into the conduit.
This invention relates to the use of zinc(II) salts in combination with a zinc ionophore to resensitize a previously resistant pathogenic bacteria to an antibiotic. Methods of restoring the sensitivity of a resistant pathogenic bacterium to an antibiotic comprising administering a zinc ionophore in combination with a zinc(II) salt and methods of treating a bacterial infection comprising administering a zinc ionophore in combination with a zinc (II) salt concurrently and/or sequentially with administration of a therapeutically effective amount of an antibiotic is also described.
A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 5 peptide may be particularly efficacious. An S2 peptide or variant may be co- administered with the modified p145 peptide to enhance the immune response.
C07K 4/04 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from bacteria
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 5 peptide may be particularly efficacious. An S2 peptide or variant may be co- administered with the modified p145 peptide to enhance the immune response.
A61K 39/40 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum bacterial
C07K 4/04 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from bacteria
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
GOLD COAST HOSPITAL AND HEALTH SERVICE (Australia)
Inventor
Vaquette, Cedryck
Lui, Hei Man Hayman
Ivanovski, Saso
Bindra, Randy
Abstract
The present invention relates to a three-dimensional multiphasic synthetic tissue scaffold comprising first, second and third compartments, wherein: each said compartment comprises distinct microstructural, and/or chemical, and/or mechanical properties, and is connected with at least one other compartment of the scaffold via a continuous interface; the tissue scaffold is porous; and the external morphology of the tissue scaffold mimics that of a mammalian joint or a component thereof. The invention further relates to a method for producing the three dimensional multiphasic synthetic tissue scaffold using a polymeric material, the method comprising using a three-dimensional (3D) bioprinter to print the tissue scaffold by continuously deposit the polymeric material onto a platform until the tissue scaffold is produced in its entirety.
